EPSRC and MRC Centre for Doctoral Training in Systems Approaches to Biomedical Science

现在很明显，生物功能或疾病是由在许多不同规模上运作的复杂互动网络引起的。将有希望的新药和疗法转化为商业产品所需的转化工作将越来越需要系统层面的预测性数学和计算建模。生物医学科学系统方法中心旨在通过培训新一代反应灵敏的研究领导者来满足这一需求，他们能够产生和应用新的物理和数学技术，以解决与制药、生物医学、生物技术和相关部门相关的研究问题。SABS将解决来自真实世界的这些与行业相关的科学问题，并通过真正的学术和产业合作来探索这些问题。SABS将在广泛的领域提供培训和研究，包括设计和测试新的化学和生物实体，模拟生物系统，以及对复杂数据集进行可靠的分析。这些交叉学科的工作将向学生介绍前沿有机化学、化学信息学、化学和合成生物学、生物物理学、高级计算模拟、生物信息学、数据挖掘、统计分析、生物分子的物理和结构研究以及数学建模。在过去的4年里，SABS团队在牛津和整个行业建立了广泛的人脉网络。SABS将继续与其合作伙伴公司(阿斯利康、钻石光源、e-Treateutics、Evotec、GE Healthcare、葛兰素史克、Hoffmann LaRoche、InhibOx、礼来英国公司、微软、诺华、辉瑞、结构基因组联盟和UCB)以及整个大学的14个以上部门密切合作。SABS的每一名学生都将得到工业界的共同监督和共同资助，并将在授课计划和以行业为基础的研究项目中充分接触到他们的研究的行业背景。他们将发展项目管理、战略规划、领导力、团队合作、商业意识和解决问题的技能，所有这些技能都将需要将基础和医学科学的创新转化为商业产品开发。SABS将继续使用其开创性的、目前唯一的开放创新知识产权协议，该协议允许SABS财团的所有参与者看到所有研究项目的结果。参与的公司将其视为产学研合作未来的开拓性模式，因为它简化了财团内部公司间的研究合作，并改进了现有的创新和学术合作业务流程。从学术的角度来看，它允许学生参与有影响力的工业研究，同时仍能从与同龄人的研究讨论中获得好处。牛津大学在研究生培训的基础设施和与SABS相关的所有研究领域都进行了大量投资。它积极推动与外部合作者的跨学科研究，目前正在对新的Target Discovery和大数据研究所进行大量投资。SABS展示了非常强大的用户吸引力，以及招募新公司的能力；目前有三个组织正在加入过程中。在这次新的竞标中，两家公司将每名学生的现金捐款增加了一倍，达到30K英镑，并将支付所有相关的研究和旅行费用(目前平均每位学生8K英镑)；这是对SABS中心继续存在的明确承诺。我们的最低队列规模为14人，这意味着产业界将为学生提供最低210万英镑的现金资助，并为研究费用再提供56万英镑。

It is now clear that biological functions or diseases arise from complex interactive networks operating on many different scales. The translational work needed to transform promising new drugs and therapies into commercial products will increasingly require predictive mathematical and computational modelling at the systems level. The Systems Approaches to Biomedical Science (SABS) Centre aims to meet this demand by training a new generation of responsive research leaders with the ability to generate and apply novel physical and mathematical techniques to solve research problems of relevance to the pharmaceutical, biomedical, biotechnology and related sectors. SABS will address these industry-relevant scientific questions from the real world, and explore them through genuine academic-industrial collaborations.SABS will provide training and research across a wide range of areas, including the design and testing of new chemical and biological entities, modelling biological systems, and robust analysis of complex datasets. Such cross-disciplinary work will introduce students to cutting edge organic chemistry, chemoinformatics, chemical and synthetic biology, biophysics, advanced computational simulation, bioinformatics, data mining, statistical analysis, physical and structural study of biomolecules, and mathematical modelling. Over the last 4 years the SABS team have created a wide network of contacts within Oxford and across industry. SABS will continue to work closely with its partner companies (AstraZeneca, Diamond Light Source, e-Therapeutics, Evotec, GE Healthcare, GlaxoSmithKline, Hoffmann LaRoche, InhibOx, Lilly UK, Microsoft, Novartis, Pfizer, Structural Genomics Consortium and UCB), and with 14+ departments across the University. Every SABS student will be co-supervised and co-funded by industry and will be fully exposed to the industrial context of their research in both the taught programme, and in their industry-based research projects. They will develop skills in project management, strategic planning, leadership, team working, commercial awareness, and problem solving all of which will be required to translate innovations in basic and medical science into commercial product development.SABS will continue to use its ground-breaking and, currently, unique Open Innovation IP agreement, which allows all participants in the SABS consortium to see the results of all research projects. Participating companies regard it as a trail-blazing model for the future of industry-academia collaboration, because it simplifies inter-company research collaboration within the consortium and improves the existing business process for innovation and academic collaborations. From an academic perspective, it allows the students to participate in impactful industrial research whilst still gaining the benefits of research discussion with their peer cohort. Oxford University has made substantial investments both in infrastructure for graduate training and all research areas associated with SABS. It actively promotes interdisciplinary research with external collaborators, and is currently investing heavily in the new Target Discovery and Big Data institutes. SABS has demonstrated very strong user pull, and an ability to recruit new companies; three organisations are currently in the process of joining. In this new bid the companies have doubled their cash contribution per student to £30k, and will also cover all associated research and travel costs (currently averaging £8k per student); a clear commitment to the continuation of the SABS centre. Our minimum cohort size of 14 means industry will make a minimum cash contribution to student funding of £2.1m and a further £560k to research costs.